Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Watchlist Manager
Brainstorm Cell Therapeutics Inc Logo
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Watchlist
Price: 0.5625 USD -6.23% Market Closed
Market Cap: 6.2m USD

Brainstorm Cell Therapeutics Inc
Depreciation & Amortization

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Brainstorm Cell Therapeutics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Depreciation & Amortization
$228k
CAGR 3-Years
-5%
CAGR 5-Years
6%
CAGR 10-Years
9%
Abbvie Inc
NYSE:ABBV
Depreciation & Amortization
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
27%
Gilead Sciences Inc
NASDAQ:GILD
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Depreciation & Amortization
$200.6m
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Depreciation & Amortization
$525.1m
CAGR 3-Years
18%
CAGR 5-Years
18%
CAGR 10-Years
23%
No Stocks Found

Brainstorm Cell Therapeutics Inc
Glance View

Market Cap
6.2m USD
Industry
Biotechnology

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2003-05-28. The firm is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.

BCLI Intrinsic Value
Not Available

See Also

What is Brainstorm Cell Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
228k USD

Based on the financial report for Mar 31, 2025, Brainstorm Cell Therapeutics Inc's Depreciation & Amortization amounts to 228k USD.

What is Brainstorm Cell Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
9%

Over the last year, the Depreciation & Amortization growth was -12%. The average annual Depreciation & Amortization growth rates for Brainstorm Cell Therapeutics Inc have been -5% over the past three years , 6% over the past five years , and 9% over the past ten years .

Back to Top